Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2010
02/11/2010US20100035940 Cyclin Dependent Kinase Inhibitors
02/11/2010US20100035939 Penetrating carrier, anti-fungal composition using the same and method for treatment of dermatophytes
02/11/2010US20100035938 Cooling Compounds
02/11/2010US20100035937 Solubilized non-steroidal anti-inflammatory drugs
02/11/2010US20100035936 Heterocyclyl substituted tetrahydronaphthalene derivatives as 5-ht7 receptor ligands
02/11/2010US20100035935 Anthranilamide compounds, process for their production and pesticides containing them
02/11/2010US20100035934 Pyridinyl-pyrazole derivatives and their use as potassium channel modulators
02/11/2010US20100035933 Kits, Recloseable Containers, Blanks And Methods Of Treatment
02/11/2010US20100035932 Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof
02/11/2010US20100035931 Tripyridyl carboxamide orexin receptor antagonists
02/11/2010US20100035930 UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa
02/11/2010US20100035929 Unnatural dispyrin analogues, preparation and uses thereof
02/11/2010US20100035928 Method Of Treating Attention Deficit Disorders With D-Threo Methylphenidate
02/11/2010US20100035927 Medicament for prophylactic and/or therapeutic treatment of alzheimer-type dementia
02/11/2010US20100035926 Pyrazole derivatives as non-steroidal glucocorticoid receptor ligands
02/11/2010US20100035925 Compounds, pharmaceutical compositions an dmethods for inhibiting hiv infectivity
02/11/2010US20100035924 Novel 4-amino-pyridine derivatives and their use as potassium channel modulators
02/11/2010US20100035923 Vr1 vanilloid receptor antagonists with a iononic substructure
02/11/2010US20100035922 Quinuclidine carbonate salts and medicinal composition thereof
02/11/2010US20100035921 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
02/11/2010US20100035920 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE
02/11/2010US20100035919 Compounds useful as inhibitors of protein kinases
02/11/2010US20100035918 Imidazolone Compounds and Methods of Making and Using the Same
02/11/2010US20100035917 Pyrrolo[2,3-b]pyridin-4-yl-benzenesulfonamide compounds as 1kk2 inhibitors
02/11/2010US20100035916 Azabicycloalkane derivatives, preparation thereof and use thereof in therapy
02/11/2010US20100035915 Indolizine derivatives and the use thereof as antidiabetics
02/11/2010US20100035914 Azabicyclic compounds as inhibitors of monoamines reuptake
02/11/2010US20100035913 Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiestrase (PDE) 4 inhibitors
02/11/2010US20100035912 Small Molecule Inhibitors of Retroviral Assembly and Maturation
02/11/2010US20100035911 Drug combinations to treat hyperproliferative disorders
02/11/2010US20100035910 Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts
02/11/2010US20100035909 Novel substituted diaza-spiro-pyridinone derivatives for use in mch-1 mediated diseases
02/11/2010US20100035908 Substituted acetophenones useful as pde4 inhibitors
02/11/2010US20100035907 New 2,4-dianilinopyrimidines, preparation thereof as drugs, pharmaceutical compositions and use thereof essentially as ikk inhibitors
02/11/2010US20100035906 Dipyridyl-dihydropyrazolones and their use
02/11/2010US20100035904 Phenobarbital salts; methods of making; and methods of use thereof
02/11/2010US20100035903 administering 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile or salts, for the treatment of dermatitis, Crohn's disease, inflammatory bowel disease, transplant rejection, lupus, multiple sclerosis, arthritis, psoriasis, diabetes and autoimmune diseases
02/11/2010US20100035902 5-aryl-substituted dihydropyridopyrimidines and dihydropyridazines and use thereof as mineral corticoid antagonists
02/11/2010US20100035901 Adenine derivative as inhibitors of hsp90 for the treatment of cancer
02/11/2010US20100035900 6-Arylmethyl-substituted pyrazolopyrimidines
02/11/2010US20100035899 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY
02/11/2010US20100035898 Organic compounds
02/11/2010US20100035897 Pyridine, pyrimidine and pyrazine derivatives as gpcr agonists
02/11/2010US20100035896 Combination of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic cytotoxic agent
02/11/2010US20100035895 2-aminocarbonyl-pyridine derivatives
02/11/2010US20100035894 Aqueous liquid preparation having improved intraocular gatifloxacin penetration
02/11/2010US20100035893 Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof
02/11/2010US20100035892 Method for assembling high-purity chemical libraries, compounds suppressing acetyl coenzyme a carboxylase activities discovered by same
02/11/2010US20100035891 Pharmaceutically Active Compounds
02/11/2010US20100035890 Use of ranolazine for the treatment of cardiovascular diseases
02/11/2010US20100035889 Use of PDE III Inhibitors For The Treatment of Asymptomatic (Occult) Heart Failure
02/11/2010US20100035888 Diaryl Urea for Treating Pulmonary Hypertension
02/11/2010US20100035887 Therapeutic compounds for blocking dna synthesis of pox viruses
02/11/2010US20100035886 Parenteral formulations of dopamine agonists
02/11/2010US20100035885 Compositions for manipulating the lifespan and stress response of cells and organisms
02/11/2010US20100035884 Kinase inhibitor
02/11/2010US20100035883 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
02/11/2010US20100035882 Inhibition of pde2a
02/11/2010US20100035880 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as vr1 receptor antagonists
02/11/2010US20100035879 N-sulfonylcarboximidamide apoptosis promoters
02/11/2010US20100035878 Inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation
02/11/2010US20100035877 Methods and compositions for treating pathologies associated with bdnf signaling
02/11/2010US20100035876 Use of a Kinase Inhibitor for the Treatment of Particular Resistant Tumors
02/11/2010US20100035875 Triazolopyridine jak inhibitor compounds and methods
02/11/2010US20100035874 Organic compounds
02/11/2010US20100035873 Diaryl Compounds and Uses Thereof
02/11/2010US20100035872 Pde10 inhibitors and related compositions and methods
02/11/2010US20100035871 Benzoxazine derivatives and uses thereof
02/11/2010US20100035870 Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds
02/11/2010US20100035869 Targeted nitroxide agents
02/11/2010US20100035868 Methods of treatment of uterine pathological conditions
02/11/2010US20100035867 Inhibitors of Cyclic Nucleotide Synthesis and Their Use for Therapy of Various Diseases
02/11/2010US20100035866 Novel substituted-1, 1-dioxo-benzo[1,2,4]thiadiazin-3ones, preparation method thereof, and pharmaceutical composition containing the same
02/11/2010US20100035865 Sulfonamides and Pharmaceutical Compositions Thereof
02/11/2010US20100035864 2,2-Dimethyl-4-oxo-4-(4-{4-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-phenyl}-[1,4]diazepan-1-yl)-butyric acid, hydrochloride; obesity, type II diabetes mellitus and metabolic syndrome
02/11/2010US20100035863 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions
02/11/2010US20100035862 Novel aza-cyclic indole-2-carboxamides and methods of use thereof
02/11/2010US20100035861 Meptazinol Biligand Derivatives and/or their Salts, Preparation Method and Uses Thereof
02/11/2010US20100035860 Inhibitors of protein tyrosine phosphatase for the promotion of physiological cardiac hypertrophy
02/11/2010US20100035859 Treatment of protein aggregation diseases
02/11/2010US20100035858 Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor
02/11/2010US20100035857 N-[3-(4-{(2S,3R)-2-(-(4-{[(2S, 5S, 3R, 4R, 6R)-3,4,5-trihydroxy-6-(hydroxymethyl)perhydro-2H-pyran-2-yl]ethyl-2-yl}phenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-1-yl}phenyl)propyl]-N-methylmethanesulfonamide; anticholesterol agent; low density lipoprotein; treating atherosclerosis
02/11/2010US20100035856 Beta-LACTAM-CONTAINING FORMULATIONS WITH INCREASED STABILITY IN AQUEOUS SOLUTION
02/11/2010US20100035855 Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject
02/11/2010US20100035854 Dry powder formulations
02/11/2010US20100035853 Method for preventing or treating cisplatin-induced nephrotoxicity
02/11/2010US20100035852 Compositions and methods for treating inflammatory conditions of the bowel
02/11/2010US20100035851 Agent for improving insulin resistance
02/11/2010US20100035850 Method of treatment for inflammatory bowel disease
02/11/2010US20100035849 Novel methylenedioxy phenolic compounds and their use to treat disease
02/11/2010US20100035848 Therapy for disorders of the proximal digestive tract
02/11/2010US20100035847 Genes for biosynthesis of tetracycline compounds and uses thereof
02/11/2010US20100035846 Method for the treatment of acne and certain dosage forms thereof
02/11/2010US20100035845 Tigecycline formulations
02/11/2010US20100035843 Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists
02/11/2010US20100035842 Amino alcohol compounds or phosphonic acid derivatives thereof
02/11/2010US20100035841 Inhibitors of tyrosine kinases and uses thereof
02/11/2010US20100035839 Merocyanine derivatives
02/11/2010US20100035838 Cross-linked polysaccharide gels
02/11/2010US20100035837 Therapeutic or prophylactic agent for vasoconstriction